This open-label, multicenter, randomized phase IV trial (NCT01498822) of noninferiority design compared the long-term effectiveness, safety, and tolerability of levetiracetam (LEV) monotherapy with those of oxcarbazepine (OXC) monotherapy in adults with newly diagnosed focal epilepsy. Korean patients (16-80 years), with ≥2 unprovoked focal seizures in the year preceding the trial, who had not taken any antiepileptic drugs (AEDs) in the last 6 months, were randomized to receive LEV or OXC (1:1). Effectiveness, safety, and tolerability were assessed over a 50-week period. Treatment failure rates (per protocol set) were 15/118 (12.7%) in the LEV-treated group and 30/128 (23.4%) in the OXC-treated group, an absolute difference of À10.7% (95% confidence interval [CI] À20.2, À1.2). Because the upper 95% CI limit was less than the pre-specified noninferiority margin of 15%, LEV was considered noninferior to OXC. Twenty-four-week and 48-week seizure freedom rates were 53.8% and 34.7% for LEV vs. 58.5% and 40.9% for OXC. Both LEV and OXC were well tolerated, with 8.7% and 8.6% of patients reporting serious treatment-emergent adverse events, respectively. By comparing LEV with OXC, another newer AED, LEV can be considered a useful option as initial monotherapy for patients with newly diagnosed focal epilepsy.
LEV has broad-spectrum efficacy, as shown in the Keppra vs. Older Monotherapy in Epilepsy Trial (KOMET) study, 3 where time-to-treatment withdrawal suggested similarity between LEV and controlled-release (CR) CBZ monotherapy for focal seizures, and extended-release valproic acid monotherapy for generalized seizures. These LEV clinical trials were undertaken largely in Western populations. Open-label studies of LEV in adults with focal epilepsy have been carried out in a number of Asian countries; [4] [5] [6] [7] however, these have all investigated LEV as adjunctive therapy rather than as initial monotherapy.
The open-label phase IV trial described herein was conducted in South Korea in order to expand the available data for the effectiveness of LEV monotherapy in Asian populations. Oxcarbazepine (OXC), another newer AED, was chosen as the comparator. OXC has generally been shown to have a similar efficacy, but improved tolerability and safety, when compared with older AEDs such as CBZ. 8, 9 This trial is the first head-to-head comparison of the effectiveness, safety, and tolerability of the newer AEDs LEV and OXC, as monotherapy for the treatment of newly diagnosed focal epilepsy.
Methods

Patients
Patients with newly or recently diagnosed epilepsy, aged 16-80 years inclusive, were eligible to participate. Patients were included if they had ≥2 unprovoked focal seizures (including generalized tonic-clonic seizures [type IIE], if it was indistinguishable from secondarily generalized seizures [type IC]) separated by ≥48 h in the year preceding randomization, with ≥1 occurring in the preceding 6 months. Patients were excluded if they had the following: treatment with AEDs ≤6 months preceding the trial; body weight <40 kg; had taken any immunosuppressants, neuroleptics, monoamine oxidase inhibitors, or narcotic analgesics ≤28 days prior to screening; a history of attempted suicide, chronic alcohol or drug abuse in ≤2 years, or status epilepticus ≤3 months prior to screening; or any clinically relevant deviation from the reference ranges of laboratory parameters.
Women who were pregnant, breastfeeding, or not using adequate contraceptive measures were also excluded.
Trial design
This open-label, multicenter, randomized (1:1) phase IV trial (NCT01498822, N01367) was conducted across 23 sites in South Korea. The trial included a 1-week screening period, 2-week uptitration period to the first dosage level of 1,000 mg/day for LEV or 900 mg/day for OXC, and 48-week treatment period (Fig. S1 ). If seizures were not controlled during the treatment period, dosages were uptitrated to 3,000 mg/day or 2,400 mg/day for LEV or OXC, respectively.
Outcome measures
The primary outcome measure was treatment failure rate (i.e., the percentage of patients who dropped out due to treatment failure at the maximum tolerated dosage [MTD] during the 50 weeks after the first dose of trial drug). Treatment failure was defined as meeting at least one of two conditions. The first condition was discontinuation for any of the following three reasons: an adverse event (AE) related to the trial drug, lack of efficacy, or the need for an additional AED. The second condition was the requirement of a one-step downtitration due to an AE related to trial drug, or not reaching the minimal approved therapeutic trial drug dose (LEV 1,000 mg/day, OXC 900 mg/day).
Secondary outcome measures were 24-and 48-week seizure freedom, defined as the number and percentage of patients who achieved seizure freedom for either 24 consecutive weeks at any time during the treatment period, or during the entire treatment period (not inclusive of the 2-week up-titration period), respectively. The time-to-treatment failure was also measured as the time from the first dose of medication to treatment failure, as defined above, during the treatment period.
Safety variables included the number and percentage of patients with treatment-emergent adverse events (TEAEs), adverse drug reactions, discontinuation rates due to an AE, laboratory assessments, electrocardiography (ECG) studies, vital signs, and neurologic examinations.
Statistical analyses
The safety set (SS) consisted of all patients who were randomized and received ≥1 (partial) dose of trial medication. The full analysis set (FAS) comprised all patients in the SS who returned ≥1 post-baseline seizure diary. The per-protocol set (PPS) was defined as patients in the FAS without any important protocol deviation that may have influenced the validity of the data. Patients who discontinued the trial before week 50 for any reason other than treatment failure were excluded from the PPS.
The aim of the primary analysis of this trial was to evaluate whether the treatment failure rate for patients treated with LEV was noninferior to that of patients treated with OXC. The noninferiority margin was set to 15%. LEV would be declared noninferior to OXC if the upper limit of the two-sided 95% confidence interval (CI) for the risk absolute difference estimate (treatment failure rate for OXC subtracted from the treatment failure rate for LEV) did not exceed 15% in the PPS. Sensitivity analysis was performed by repeating the primary outcome analysis in the FAS. CIs for differences in proportions were calculated using Wald approximation. Corresponding p-values for the comparison of two proportions were obtained using two-proportion Ztests. Time-to-treatment failure was analyzed using KaplanMeier methods.
Sample size calculations were based on the treatment failure rate for the comparison of LEV with OXC. In a previous trial of OXC and phenytoin, 10 treatment failure rate of OXC was observed to be 39.2%, which could be assumed for OXC and LEV in the current trial. The assumed dropout rate, to allow for patients with seizures indistinguishable between type IC and IIE to be excluded from the PPS, was 5%. Therefore, to statistically confirm noninferiority by a margin of 15%, the number of randomized patients needed in each treatment group was evaluated to be 176 (352 in total). 
Results
Patients
Overall, 353 patients were randomized to LEV (N = 175) or OXC (N = 178). Three hundred forty-seven patients (98.3%) were included in the SS, 344 (97.5%) in the FAS, and 246 (69.7%) in the PPS. Of those randomized, 243 patients (68.8%) completed the trial and 110 patients (31.2%) discontinued the trial. Patients in each treatment group discontinued the trial at a similar incidence, although slightly lower percentages of patients in the LEV group discontinued due to consent withdrawal or AEs compared with the OXC group (Fig. 1) .
The LEV and OXC treatment groups had similar demographics and baseline characteristics (Table S1) , although there was a slightly longer mean duration of epilepsy at trial entry in the LEV group (1.85 months) vs. the OXC group (0.92 months). Most of the patients had a history of secondarily generalized seizures (66.9%) or complex partial seizures (48.7%).
Outcome measures
Treatment failure was reported in 15 (12.7%) of 118 patients in the LEV-treated group, compared with 30 (23.4%) of 128 in the OXC-treated group (PPS; Table 1 ). The absolute difference in treatment failure rate between the two treatment arms (LEV vs. OXC) was À10.7%. The upper limit of the two-sided 95% CI (À1.2%) for absolute difference in treatment failure rate did not exceed the selected noninferiority margin of +15%, indicating that treatment with LEV was noninferior to treatment with OXC. This is supported by results for the FAS, where 11.0% of patients in the LEV-treated group were treatment failures compared with 18.1% of patients in the OXC-treated group (Table 1) . The upper limit of the two-sided 95% CI (0.3%) was also below the noninferiority margin.
Twenty-four-week seizure freedom rates were similar for LEV and OXC, but 48-week seizure freedom rates were numerically lower for LEV than OXC (exploratory 2-proportion Z-test p-value = 0.2317) ( Table 1 ; FAS). Based on Kaplan-Meier estimates, the hazard ratio for time-totreatment failure of LEV vs. OXC was 0.6 (95% CI 0.3-1.0), indicating a 40% reduction in hazard of treatment failure for patients receiving LEV compared with patients receiving OXC (FAS exploratory log-rank test p-value = 0.0658).
Safety and tolerability
Median duration of exposure to trial medication was 350 days for both LEV and OXC treatment groups. Mean daily dose of LEV and OXC over the trial was 1,170.23 and 996.91 mg/day, respectively.
A total of 344 and 407 TEAEs, respectively, were reported by 117 (67.6%) of 173 patients in the LEV group and 130 (74.7%) of 174 patients in the OXC group; 8.7% and 8.6% of patients treated with LEV or OXC, respectively, reported ≥1 serious TEAE. The incidence of patients with TEAEs requiring a dose reduction was 10 (5.8%) of 173 in the LEV-treated group and 19 (10.9%) of 174 in the OXC group. TEAEs observed in ≥5% of patients treated with LEV or OXC were dizziness (15.0% vs. 28.7%), headache (14.5% vs. 20.7%), somnolence (12.7% vs. 13.8%), nasopharyngitis (8.1% vs. 10.9%), and rash (1.7% vs. 7.5%). A summary of the TEAEs is shown in Table S2 . There was no evidence of any effect of trial medication on laboratory parameters, vital signs, ECG findings, or neurologic examinations.
Discussion
The open-label, randomized phase IV trial reported herein was the first LEV monotherapy trial to be conducted in an Asian population, and the first head-to-head trial between LEV and OXC (two newer AEDs). Using treatment failure rate as the primary outcome measure, LEV monotherapy was shown to be noninferior to OXC in the treatment of Korean patients with focal epilepsy.
Both drugs were well tolerated; incidence of serious TEAEs was similar between LEV and OXC. Incidence of all TEAEs was lower with LEV than OXC (67.6% vs. 74.7%), as was the incidence of TEAEs resulting in dose reduction (5.8% vs. 10.9%). This trial helps to confirm previous data that initial monotherapy with LEV may be beneficial for patients with newly diagnosed focal epilepsy. Previous clinical trials compared LEV monotherapy with CBZ-CR monotherapy as the standard first-line treatment for patients with focal epilepsy. 2, 3 Herein, we present the first direct comparison of LEV and OXC as monotherapy for adults with focal epilepsy. OXC was chosen as a comparator rather than CBZ, since the Standard and New Antiepileptic Drugs (SANAD) study, 9 an unblinded, randomized controlled trial carried out in the United Kingdom, indicated similarities in clinical outcomes between OXC and CBZ. Moreover, some newer AEDs do not possess the auto-induction and drug-interaction properties of CBZ, and may be better tolerated. A previous comparison of LEV and OXC monotherapy has been made in a different population (i.e., children with newly diagnosed benign epilepsy with centrotemporal spikes). 11 Preliminary data from this openlabel, parallel-group trial also indicated similar efficacy and tolerability for LEV and OXC.
Limitations of this trial include its open-label design (which may have introduced bias into the findings) and the analysis of Korean patients only (which may limit the application of the findings to other patient populations).
Conclusion
LEV monotherapy was found to be noninferior to OXC monotherapy, with regard to treatment failure, in a population of Korean patients with newly diagnosed focal epilepsy. The findings of this trial can help clinicians in the selection of effective and well-tolerated agents for the longterm treatment of their patients.
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